Skip to main content
Top
Published in: Journal of Endocrinological Investigation 5/2020

01-05-2020 | Endogenous Cushing's Syndrome | Original Article

Determinants of outcome of transsphenoidal surgery for Cushing disease in a single-centre series

Authors: A. L. Serban, G. Del Sindaco, E. Sala, G. Carosi, R. Indirli, G. Rodari, C. Giavoli, M. Locatelli, G. Carrabba, G. Bertani, G. Marfia, G. Mantovani, M. Arosio, E. Ferrante

Published in: Journal of Endocrinological Investigation | Issue 5/2020

Login to get access

Abstract

Background

First-line therapy of Cushing disease (CD) is transsphenoidal surgery (TSS) aimed to obtain a complete removal of the pituitary adenoma and remission of disease.

Purpose

To analyse the surgical outcome of patients with CD who underwent TSS in our Centre.

Methods

Retrospective analysis on patients with CD who underwent TSS between 1990 and 2016.

Results

We analysed 102 TSS that included: 84 first TSS and 18 second and third TSS. The overall remission rate after surgery was 76.5%, with a significant higher percentage of remitted patients after the first TSS compared to the subsequent TSS (82% vs 50%, p = 0.014). The remission after the first TSS was significantly higher when performed by a dedicated surgical team (DST) (89.8% vs 71% p = 0.04) and when the immunohistochemical examination confirmed the adrenocorticotropic adenoma (87% vs 55%, p = 0.04). Neuroradiological findings influenced the surgical outcome in a non-significant manner. Post-TSS complications were reported in 32 patients, with no significant variation when TSS was performed by DST. In case of reintervention, remission of disease was obtained in 72.7% of microadenoma, while no remitted patients were observed in case of macroadenomas. The DST did not significantly improve the outcome.

Conclusion

Cushing disease is characterized by a broad spectrum of neuroradiological presentation. Despite the availability of a DST make the TSS a safe and effective first-line treatment among all these patients, a precise pre-treatment evaluation is needed in order to define the aim of neurosurgery and to schedule the management of recurrent disease.
Literature
6.
go back to reference Petersenn S, Beckers A, Ferone D et al (2015) Therapy of endocrine disease: outcomes in patients with Cushing’s disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. Eur J Endocrinol 172:R227–R239. https://doi.org/10.1530/EJE-14-0883 CrossRefPubMed Petersenn S, Beckers A, Ferone D et al (2015) Therapy of endocrine disease: outcomes in patients with Cushing’s disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. Eur J Endocrinol 172:R227–R239. https://​doi.​org/​10.​1530/​EJE-14-0883 CrossRefPubMed
17.
go back to reference Ambrosi B, Barbetta L, Re T et al (1998) The one microgram adrenocorticotropin test in the assessment of hypothalamic-pituitary-adrenal function. Eur J Endocrinol 139:575–579CrossRefPubMed Ambrosi B, Barbetta L, Re T et al (1998) The one microgram adrenocorticotropin test in the assessment of hypothalamic-pituitary-adrenal function. Eur J Endocrinol 139:575–579CrossRefPubMed
Metadata
Title
Determinants of outcome of transsphenoidal surgery for Cushing disease in a single-centre series
Authors
A. L. Serban
G. Del Sindaco
E. Sala
G. Carosi
R. Indirli
G. Rodari
C. Giavoli
M. Locatelli
G. Carrabba
G. Bertani
G. Marfia
G. Mantovani
M. Arosio
E. Ferrante
Publication date
01-05-2020
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation / Issue 5/2020
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-019-01151-1

Other articles of this Issue 5/2020

Journal of Endocrinological Investigation 5/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.